Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,616 GBX | +1.46% | +3.14% | +0.95% |
02/04 | RBC Lifts Diploma PT, Maintains Sector Perform Rating | MT |
02/04 | Bernstein starts AstraZeneca at 'outperform' | AN |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- With an expected P/E ratio at 32.51 and 28.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.81 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.95% | 6.04B | C | ||
+12.14% | 45.6B | A- | ||
+5.25% | 39.03B | B | ||
+4.75% | 6.99B | C+ | ||
-7.94% | 5.25B | B | ||
+29.24% | 1.59B | C+ | ||
+4.63% | 1.55B | D+ | ||
+3.80% | 1.06B | - | ||
-5.74% | 991M | - | - | |
+5.36% | 988M | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DPLM Stock
- Ratings Diploma PLC